Topic: Colorectal Cancer Progression and Treatment

Download All Articles

A special issue of Journal of Cancer Metastasis and Treatment  (Print ISSN:2394-4722; Online ISSN:2454-2857).

Deadline for manuscript submissions: 30 Jun 2018

Share This Special Issue

Guest Editor(s)

  • Prof. Guofeng Xie, MD, PhD
    Department of Medicine, Division of Gastroenterology & Hepatology and Program in Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.

    Website | E-mail

Special Issue Introduction:

Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. Although curative treatment options for advanced disease are still lacking, rapid progress has been made in the last decade in understanding the molecular mechanisms underlying CRC tumorigenesis and progression. Also, robust preventive measures and novel therapies resulted in decreased CRC incidence and improved survival. Reviews in this special issue will allow readers to gain insights into the current states of CRC prevention, detection, treatment and its unique molecular mechanisms.

Keywords:

Epidemiology; molecular mechanisms underlying CRC tumorigenesis, invasion and metastasis; role of genetic and epigenetic modifications; role of microRNAs; role of diet, intestinal microbiota and immune system; animal and enteroid models; tumor markers in CRC; CRC prevention, detection and therapy

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://mc03.manuscriptcentral.com/jcmt
Submission Deadline: 30 Jun 2018
Contacts: Carrie Wang, Managing Editor, editor001@jcmtjournal.com

Published Articles Download All Articles
  • Immunotherapy in the treatment of colorectal cancer: a new kid on the block

    Andrea Spallanzani , Fabio Gelsomino , Francesco Caputo , Chiara Santini , Kalliopi Andrikou , Giulia Orsi , Margherita Rimini , Stefania Pipitone , Laura Riggi , Camilla Bardasi , Massimiliano Salati , Stefano Cascinu
    In the last few years, the success of anti-PD1 and anti-PDL1 drugs in solid cancers treatment and the advances in molecular biology have provided new potential treatment strategies for patients with metastatic colorectal cancer. Unfortunately, only patients with mismatch repair deficiency seem to benefit from immunotherapy and they represent a small subset of the metastatic population. New ongoing studies focus on converting an immune ignorant tumour into an inflamed one by combination therapies and on introducing an immunotherapeutic approach in earlier stages of disease (neoadjuvant and... Read more
    This article belongs to the Special Issue Colorectal Cancer Progression and Treatment
    J Cancer Metastasis Treat 2018;4:28. | doi:10.20517/2394-4722.2018.31
    Published on: 19 Jun 2018  | Viewed:120  | Downloaded:9
    +HTML| PDF
Journal of Cancer Metastasis and Treatment ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.